tipifarnib: Clinical Trials

36 trials of tipifarnib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

30 completed, 4 terminated, 1 unknown, 1 withdrawn. 36 Phase 1, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 136Completed 30, Terminated 4, Unknown 1, Withdrawn 1
Phase 212Completed 10, Terminated 2

Follow tipifarnib: new trials by email Literature Review of tipifarnib trials Research Report on tipifarnib

Trials (filtered) newest first · largest first

All 36 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Tipifarnib, Osimertinib - NSCLC
Phase 1WithdrawnKura Oncology, Inc.2023-02-012023-03-06
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Tipifarnib, Alpelisib - HNSCC
Phase 1 / Phase 2CompletedKura Oncology, Inc.452021-12-072026-09-08
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
Tipifarnib - Advanced Solid Tumor
Phase 1TerminatedKura Oncology, Inc.62021-05-062023-09-21
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
tipifarnib, paclitaxel, doxorubicin - Breast Cancer, Male Breast Cancer
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)602007-04-012021-02-16
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
cytarabine, daunorubicin hydrochloride, tipifarnib - Leukemia
Phase 1CompletedUniversity Health Network, Toronto242007-04-012015-07-23
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Bortezomib and Tipifarnib - Multiple Myeloma
Phase 1CompletedEmory University122006-12-012015-03-10
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
Bortezomib, Laboratory Biomarker Analysis, Tipifarnib - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Phase 1CompletedNational Cancer Institute (NCI)352006-08-012015-04-15
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
sorafenib tosylate, erlotinib hydrochloride, tipifarnib - Adult Giant Cell Glioblastoma, Adult Glioblastoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)922006-04-012018-07-02
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
cytarabine, daunorubicin hydrochloride, etoposide - Leukemia
Phase 1TerminatedOhio State University Comprehensive Cancer Center302006-03-012013-05-03
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
Laboratory Biomarker Analysis, Sorafenib Tosylate, Tipifarnib - Advanced Malignant Neoplasm
Phase 1CompletedNational Cancer Institute (NCI)742005-10-012017-04-27
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
Gemcitabine Hydrochloride, Tipifarnib, Laboratory Biomarker Analysis - Recurrent Breast Carcinoma, Stage IV Breast Cancer
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)312005-09-012015-01-13
A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma
PS-341, R11577 - Multiple Myeloma
Phase 1 / Phase 2TerminatedH. Lee Moffitt Cancer Center and Research Institute422005-08-012013-11-25
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
bortezomib, tipifarnib, laboratory biomarker analysis - Refractory Multiple Myeloma, Stage II Multiple Myeloma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)642005-08-012013-10-08
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
tipifarnib, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Phase 1CompletedNational Cancer Institute (NCI)1002005-03-012013-01-09
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
tipifarnib, pharmacological study, laboratory biomarker analysis - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Erythroid Leukemia (M6)
Phase 1CompletedNational Cancer Institute (NCI)302004-10-012013-02-04
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
cytarabine, idarubicin, tipifarnib - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)952004-09-012014-05-26
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Solid Neoplasm
Phase 1CompletedNational Cancer Institute (NCI)292004-05-202018-05-18
Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
radiation therapy, tipifarnib - Untreated Childhood Brain Stem Glioma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)512004-01-012014-05-15
Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer
tipifarnib, radiation therapy - Pancreatic Cancer
Phase 1CompletedAbramson Cancer Center at Penn Medicine182004-01-012020-04-15
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
Capecitabine, Docetaxel, Laboratory Biomarker Analysis - Adult Solid Neoplasm, Inflammatory Breast Carcinoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)532003-09-012015-05-04

Showing 20 of 36. Sign in to see all of them.

Conditions studied

Leukemia, Myeloid, Acute (7)  ·  Congenital Abnormalities (5)  ·  Glioblastoma (5)  ·  Leukemia (5)  ·  Leukemia, Erythroblastic, Acute (5)  ·  Leukemia, Megakaryoblastic, Acute (5)  ·  Leukemia, Monocytic, Acute (5)  ·  Leukemia, Myelomonocytic, Acute (5)  ·  Blast Crisis (4)  ·  Brain Neoplasms (4)  ·  Breast Neoplasms (4)  ·  Gliosarcoma (4)  ·  Leukemia, Myelomonocytic, Chronic (4)  ·  Multiple Myeloma (4)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)

Sponsors

National Cancer Institute (NCI) (18)  ·  Kura Oncology, Inc. (3)  ·  Abramson Cancer Center at Penn Medicine (2)  ·  M.D. Anderson Cancer Center (2)  ·  City of Hope Medical Center (1)  ·  Emory University (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  NYU Langone Health (1)  ·  National Center for Research Resources (NCRR) (1)  ·  National Institutes of Health Clinical Center (CC) (1)  ·  Ohio State University Comprehensive Cancer Center (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  The University of Texas Health Science Center at San Antonio (1)  ·  University Health Network, Toronto (1)  ·  University of Maryland, Baltimore (1)

Countries

United States (35)  ·  Canada (3)  ·  Australia (1)

Top investigators

Stephen Michael Hahn, MD (2)  ·  Timothy Cloughesy (2)  ·  Anthony W. Tolcher, MD (1)  ·  Banu Arun (1)  ·  Brigitte C. Widemann, MD (1)  ·  Daphne Haas-Kogan (1)  ·  Darrin Beaupre (1)  ·  David Hong (1)  ·  David Sommerhalder, MD (1)  ·  Dawn Hershman (1)  ·  Eric K. Rowinsky, MD (1)  ·  Howard S. Hochster, MD (1)  ·  Jeffrey Lancet (1)  ·  Jorge Cortes (1)  ·  Jorge E Cortes, MD (1)

Results publications

PMID 15570084, PMID 15711184, PMID 16170172, PMID 16877733, PMID 19092853, PMID 19109557, PMID 20860038, PMID 23676418, PMID 24068539

NIH funding

N01CM62202 (3), N01CM62204 (2), P30CA015083 (2), P30CA016672 (2), U01CA062399 (2), U01CA062461 (2), U01CA062505 (2), M01RR000096 (1), N01CM17003 (1), N01CM62205 (1), N01CM62208 (1), P30CA013330 (1), P30CA033572 (1), P30CA054174 (1), P30CA076292 (1)